|
Gastroenterology
Reversal of liver cirrhosis: current evidence and expectations
Young Kul Jung, Hyung Joon Yim
Korean J Intern Med. 2017;32(2):213-228. Published online February 8, 2017
In the past, liver cirrhosis was considered an irreversible phenomenon. However, many experimental data have provided evidence of the reversibility of liver fibrosis. Moreover, multiple clinical studies have also shown regression of fibrosis and reversal of cirrhosis on repeated biopsy samples. As v..
|
|
|
Hemato-oncology
Guidelines for the management of myeloproliferative neoplasms
Chul Won Choi, Soo-Mee Bang, Seongsoo Jang, Chul Won Jung, Hee-Jin Kim, Ho Young Kim, Soo-Jeong Kim, Yeo-Kyeoung Kim, Jinny Park, Jong-Ho Won
Korean J Intern Med. 2015;30(6):771-788. Published online October 30, 2015
Polycythemia vera, essential thrombocythemia, and primary myelofibrosis are collectively known as ‘Philadelphia-negative classical myeloproliferative neoplasms (MPNs).’ The discovery of new genetic aberrations such as Janus kinase 2 (JAK2) have enhanced our understanding of the pathophysio..
|
|
|
Gastroenterology
Mesenchymal stem cell therapy for liver fibrosis
Young Woo Eom, Kwang Yong Shim, Soon Koo Baik
Korean J Intern Med. 2015;30(5):580-589. Published online August 27, 2015
Currently, the most effective treatment for end-stage liver fibrosis is liver transplantation; however, transplantation is limited by a shortage of donor organs, surgical complications, immunological rejection, and high medical costs. Recently, mesenchymal stem cell (MSC) therapy has been suggested ..
|
|
|
Pulmonology
Modifiers of TGF-b1 effector function as novel therapeutic targets of pulmonary fibrosis
Chang-Min Lee, Jin Wook Park, Won-Kyung Cho, Yang Zhou, Boram Han, Pyoung Oh Yoon, Jeiwook Chae, Jack A Elias, Chun Geun Lee
Korean J Intern Med. 2014;29(3):281-290. Published online April 29, 2014
Pulmonary fibrosis is a fatal progressive disease with no effective therapy. Transforming growth factor (TGF)-b1 has long been regarded as a central mediator of tissue fibrosis that involves multiple organs including skin, liver, kidney, and lung. Thus, TGF-b1 and its signaling pathways have been at..
|
|
|
Nephrology
Encapsulating peritoneal sclerosis: case series from a university center
Kyung-Deuk Hong, Ji Hea Bae, Yun-Jin Jang, Hee-Yeon Jung, Jang-Hee Cho, Ji-Young Choi, Chan-Duck Kim, Yong-Lim Kim, Sun-Hee Park
Korean J Intern Med. 2013;28(5):587-593. Published online August 14, 2013
Background/AimsEncapsulating peritoneal sclerosis (EPS) is an often-fatal complication of long-term peritoneal dialysis (PD). We here report the clinical features of EPS in Korean PD patients from a single university center. MethodsThe data were..
|
|
|
Pulmonology
Relationship between bronchial anthracofibrosis and endobronchial tuberculosis
Hyun Ji Kim, Sang Dong Kim, Dong Woo Shin, Soo Hyun Bae, Ah Lim Kim, Ji Na Kim, Seung Wook Jung, Byung Ki Lee, Yeon Jae Kim
Korean J Intern Med. 2013;28(3):330-338. Published online May 1, 2013
Background/AimsVarious pulmonary diseases may be associated with bronchial anthracofibrosis (BAF). Our aim was to identify a relationship between BAF and endobronchial tuberculosis (EBTB). MethodsIn total, 156 patients, diagnosed with EBTB using..
|
|
|
Diagnostic Usefulness of the Janus Kinase 2 Mutation in non BCR/ABL Myeloproliferative Disorders
Soo-Mee Bang, Jeong Yeal Ahn, Jiyoon Park, Soo Jin Yoo, Se Hoon Park, Eun Mi Nam, Pil Whan Park, Yiel Hea Seo, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
Korean J Intern Med. 2006;21(4):219-224. Published online December 31, 2006
BackgroundWe investigated the Janus kinase 2 (JAK2) mutation and its diagnostic value in patients suffering with non BCR/ABL myeloproliferative diseases (nMPD) or other reactive conditions. Methods..
|
|
|
